Ocugen is trading 5.00% down at MXN 15.20, with broader risk-off pressure amid hotter-than-expected U.S. producer-price inflation the likeliest context, though a direct cause is unconfirmed.
- No clear company-specific announcement explains the decline; the October 14 OCU400 licensing deal offered potential milestone payments and royalties.
- An October 15 investor presentation highlighted pipeline progress.
- Market signals are mixed: inflation renewed rate concerns and weighed on equities, while biotech was higher.